Independent biotech drug intelligence

Clinical drug trial results and experimental drugs, explained

Spectral Genomics follows experimental medical drugs from early development through clinical trials and FDA review. We explain what clinical trial results actually show, how likely a drug is to succeed, and what to watch next, with every claim linked to its source.

Track drugs. Understand evidence. Evaluate probabilities.

Drug profileRegistry data Nov 19, 2026

Retatrutide

Eli Lilly and Company · Peptide (once-weekly injection)

Not yet approved

Registered trials
34
Phase 3 or later
14
  • TRIUMPH-9Active, not recruiting · Oct 2028 (est.)
  • TRIUMPH-6Active, not recruiting · Apr 2028 (est.)
  • TRIUMPH-7Active, not recruiting · Sep 2027 (est.)
  • TRIUMPH-8Active, not recruiting · Jun 2027 (est.)

FDA: not approved (openFDA, checked Nov 19, 2026). Phase 3 obesity program complete; Lilly plans to file with the FDA in Q1 2027

Sources: ClinicalTrials.gov and openFDA. Dates are primary completion. Open the full Retatrutide profile
Clinical intelligence

Clinical drug trial results: how to read the evidence

A headline that a trial “succeeded” can mean very different things. These guides explain what to check in any clinical drug trial result: the primary endpoint, statistical significance, the control group, and whether the result has been replicated.

Open the clinical drug trial tracker: upcoming readouts, stopped trials, and every trial behind our drug profiles.

Drug development

Experimental medical drugs, from discovery to approval

Most experimental drugs never reach patients. Here is how they are discovered, tested in clinical trials, and reviewed by the FDA, and what the historical odds look like at each stage.

Approved after entering Phase 1
7.9%
Approved after entering Phase 2
15.1%
Approved after reaching Phase 3
52.4%
Avg. years, Phase 1 to approval
10.5

Historical averages for 2011–2020 from BIO, Informa Pharma Intelligence, and QLS Advisors (2021). Approval figures are from the report’s likelihood-of-approval table; the 10.5 years is its average duration. They are not predictions for any individual drug.

All 15 drug development guides

Company intelligence

Drug pipeline tracking

A drug’s prospects change with every trial readout and regulatory decision. Spectral Genomics tracks experimental drugs and the companies developing them, linked to ClinicalTrials.gov, FDA records, SEC filings, and company press releases.

Drug profiles re-check trial records against ClinicalTrials.gov and FDA status against openFDA, company pipeline pages show each sponsor’s active trials by phase, and Pipeline News collects company disclosures about the drugs we track. Every milestone carries its date, its source, and a label showing whether it was company-reported.

Milestones we track

  • A clinical trial reports results
  • A primary endpoint is met or missed
  • A trial is suspended or terminated
  • A drug advances to another development phase
  • The FDA grants a regulatory designation
  • An approval or Complete Response Letter is announced
Biotechnology

The genomics behind new drugs

Drug targets backed by human genetic evidence have been about 2.6 times more likely to succeed. These guides explain the science shaping today’s experimental drugs.

What Is Genomics?

Genomics is the study of an organism's complete set of DNA, its genome, including how genes interact with each other and with the environment. It now shapes how new drugs are discovered.

What Is Precision Medicine?

Precision medicine tailors prevention and treatment to individual differences in genes, environment, and lifestyle. In drug development, it means matching a drug to the patients most likely to benefit, often using a genetic test.

How Does CRISPR Gene Editing Work?

CRISPR gene editing uses a guide RNA to lead a DNA-cutting enzyme, usually Cas9, to a precise location in the genome. The cell's repair of that cut can disable or correct a gene. The first CRISPR-based therapy was approved by the FDA in 2023.

What Are Genetic Mutations?

A genetic mutation, or variant, is a change in the DNA sequence. Some are inherited and present in every cell. Others arise during life in particular cells, as in cancer. Most have no effect, but some cause disease or change how a person responds to drugs.

What Is Proteomics?

Proteomics is the large-scale study of proteins: which proteins are present, how much of each, and how they change. Because most drugs act on proteins, proteomics is increasingly used to find drug targets and biomarkers.

What Is Whole Genome Sequencing?

Whole genome sequencing reads nearly all of a person's roughly 3 billion DNA base pairs in a single test. It finds more kinds of genetic variation than narrower tests and is increasingly used to diagnose rare diseases and to discover drug targets.

Approval odds

Approval odds, clearly labeled

Each development program on a drug profile shows how often comparable programs at the same stage went on to FDA approval, from industry-wide data for 2011–2020.

These are historical benchmarks, labeled as such, not predictions for any individual drug. We pair them with our sourced reading of each drug’s evidence.

Read the methodology

Scientific perspective

Mechanism of action, trial design, efficacy, safety, and the quality of the evidence behind each claim.

Development perspective

Pipeline stage, upcoming milestones, development risks, and what the sponsor has disclosed, kept separate from our scientific conclusions.

Read our editorial standards

FAQ

Frequently asked questions

Where can I find clinical drug trial results?

Most trials of drugs regulated by the FDA must be registered on ClinicalTrials.gov, which also posts summary results for many completed trials. Full results usually appear in peer-reviewed journals, and for approved drugs the FDA publishes its own review documents in Drugs@FDA. Spectral Genomics links each result back to these original sources and labels whether it is peer-reviewed or company-reported.

What is an experimental medical drug?

An experimental, or investigational, drug is one that has not been approved for the use being studied. In the United States it can only be tested in people under an Investigational New Drug application with the FDA, typically through Phase 1, 2, and 3 clinical trials.

How likely is an experimental drug to be approved?

Historically, about 7.9% of drugs entering Phase 1 trials were eventually approved, according to an industry analysis of 2011–2020 programs. About 15% of drugs entering Phase 2 and about 52% of drugs reaching Phase 3 went on to approval. The odds vary widely by disease area and by how patients are selected.

What is drug pipeline tracking?

Drug pipeline tracking means following a drug or a company’s portfolio of drugs as it moves through development: trial starts and results, phase changes, regulatory designations, and FDA decisions. Spectral Genomics drug profiles track each program’s registered trials and FDA status with dates and sources, and Pipeline News collects the companies’ own announcements from SEC filings and press releases.

Is Spectral Genomics investment or medical advice?

No. Spectral Genomics provides independent information for education and research. Approval odds are statistical summaries of past development programs, not recommendations to buy or sell securities, and nothing on the site is medical advice.